We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Maravai (MRVI) Advances in RNA Research With New Collaboration
Read MoreHide Full Article
Maravai LifeSciences’ (MRVI - Free Report) business, TriLink BioTechnologies, recently partnered with Johns Hopkins University to significantly enhance research in RNA therapeutics. This collaboration aims to accelerate therapeutic development through a new center within the Johns Hopkins Whiting School of Engineering, leveraging TriLink’s cutting-edge RNA synthesis technology.
Financial terms of the deal were not revealed.
Investment and Technological Contribution
TriLink BioTechnologies works as a best-in-class contract development and manufacturing organization for the synthesis of nucleic acids, nucleoside triphosphates and messenger ribonucleic acid (mRNA) capping analogs.
Under the latest collaboration, TriLink’s commitment includes providing both direct funding and access to its proprietary in vitro transcription technology, CleanScript. This technology is pivotal in advancing mRNA development, which is essential for RNA-based therapies.
The collaboration also involves providing technical expertise and essential discovery and manufacturing supplies, thereby reducing the barriers to innovative applications in RNA research.
Strategic Implication
Per Maravai LifeSciences management, this development will advance nucleic acid-based therapies. TriLink will provide Johns Hopkins researchers with the necessary tools and expertise to develop advanced therapies aimed at treating various health conditions.
As per Johns Hopkins Whiting School of Engineering, the center will enhance Johns Hopkins' RNA research community by providing access to state-of-the-art discovery tools and fostering innovation and collaboration on campus.
By combining TriLink’s innovative RNA synthesis technology with Johns Hopkins' research expertise, the partnership aims to drive transformational breakthroughs in RNA applications, ultimately improving human health.
The new center will be directed by Jeff Coller, Bloomberg Distinguished Professor of RNA Biology and Therapeutics. It will be housed within the Institute of NanoBioTechnology and is set to open this spring.
The center will consolidate experts from diverse fields such as RNA biology, genetic medicine, drug delivery and biotechnology, serving as a training ground for the next generation of RNA researchers and a collaborative hub for RNA studies across various disciplines at Johns Hopkins.
Image Source: Zacks Investment Research
Market Prospects
Going by a Roots Analysis report, the global RNA therapeutics and vaccines market is poised for robust growth, expected to surge from $1.2 million in 2023 to $948 million by 2035, at a CAGR of 68%. RNA-based therapeutics have revolutionized modern healthcare by offering superior therapeutic and safety profiles compared to traditional treatments. Despite challenges such as molecule instability and delivery issues, innovative modalities like circular RNA and self-amplifying RNA are emerging. These advancements, combined with promising clinical trials and accelerated regulatory approvals, position the RNA therapeutics market for substantial expansion, addressing previously untreatable diseases.
Share Price Performance
Year to date, shares of MRVI have surged 69.5% compared with the industry’s 4% growth.
Zacks Rank and Key Picks
Maravai LifeSciences currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace (MEDP - Free Report) , ResMed (RMD - Free Report) and Encompass Health Corporation (EHC - Free Report) .
Medpace, sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2024 EPS of $3.20, which beat the Zacks Consensus Estimate by 30.6%. Revenues of $511 million improved 17.7% from last year’s comparable figure. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace has an estimated 2024 earnings growth rate of 26.5% compared with the industry’s 12.3%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 12.8%.
ResMed, carrying a Zacks Rank #2 (Buy), reported first-quarter 2024 EPS of $2.13, which topped the Zacks Consensus Estimate by 10.9%. Revenues of $1.20 billion surpassed the Zacks Consensus Estimate by 1.9%.
RMD has an estimated fiscal 2024 earnings growth rate of 17.9% compared with the industry’s 15.7%. The company delivered an average four-quarter earnings surprise of 2.8%.
Encompass Health, carrying a Zacks Rank #2, reported first-quarter 2024 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 20.4%. Net operating revenues of $1.3 billion topped the Zacks Consensus Estimate by 3.6%.
EHC has an estimated long-term earnings growth rate of 15.6% compared with the industry’s 11.7% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.7%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Maravai (MRVI) Advances in RNA Research With New Collaboration
Maravai LifeSciences’ (MRVI - Free Report) business, TriLink BioTechnologies, recently partnered with Johns Hopkins University to significantly enhance research in RNA therapeutics. This collaboration aims to accelerate therapeutic development through a new center within the Johns Hopkins Whiting School of Engineering, leveraging TriLink’s cutting-edge RNA synthesis technology.
Financial terms of the deal were not revealed.
Investment and Technological Contribution
TriLink BioTechnologies works as a best-in-class contract development and manufacturing organization for the synthesis of nucleic acids, nucleoside triphosphates and messenger ribonucleic acid (mRNA) capping analogs.
Under the latest collaboration, TriLink’s commitment includes providing both direct funding and access to its proprietary in vitro transcription technology, CleanScript. This technology is pivotal in advancing mRNA development, which is essential for RNA-based therapies.
The collaboration also involves providing technical expertise and essential discovery and manufacturing supplies, thereby reducing the barriers to innovative applications in RNA research.
Strategic Implication
Per Maravai LifeSciences management, this development will advance nucleic acid-based therapies. TriLink will provide Johns Hopkins researchers with the necessary tools and expertise to develop advanced therapies aimed at treating various health conditions.
As per Johns Hopkins Whiting School of Engineering, the center will enhance Johns Hopkins' RNA research community by providing access to state-of-the-art discovery tools and fostering innovation and collaboration on campus.
By combining TriLink’s innovative RNA synthesis technology with Johns Hopkins' research expertise, the partnership aims to drive transformational breakthroughs in RNA applications, ultimately improving human health.
The new center will be directed by Jeff Coller, Bloomberg Distinguished Professor of RNA Biology and Therapeutics. It will be housed within the Institute of NanoBioTechnology and is set to open this spring.
The center will consolidate experts from diverse fields such as RNA biology, genetic medicine, drug delivery and biotechnology, serving as a training ground for the next generation of RNA researchers and a collaborative hub for RNA studies across various disciplines at Johns Hopkins.
Image Source: Zacks Investment Research
Market Prospects
Going by a Roots Analysis report, the global RNA therapeutics and vaccines market is poised for robust growth, expected to surge from $1.2 million in 2023 to $948 million by 2035, at a CAGR of 68%. RNA-based therapeutics have revolutionized modern healthcare by offering superior therapeutic and safety profiles compared to traditional treatments. Despite challenges such as molecule instability and delivery issues, innovative modalities like circular RNA and self-amplifying RNA are emerging. These advancements, combined with promising clinical trials and accelerated regulatory approvals, position the RNA therapeutics market for substantial expansion, addressing previously untreatable diseases.
Share Price Performance
Year to date, shares of MRVI have surged 69.5% compared with the industry’s 4% growth.
Zacks Rank and Key Picks
Maravai LifeSciences currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace (MEDP - Free Report) , ResMed (RMD - Free Report) and Encompass Health Corporation (EHC - Free Report) .
Medpace, sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2024 EPS of $3.20, which beat the Zacks Consensus Estimate by 30.6%. Revenues of $511 million improved 17.7% from last year’s comparable figure. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace has an estimated 2024 earnings growth rate of 26.5% compared with the industry’s 12.3%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 12.8%.
ResMed, carrying a Zacks Rank #2 (Buy), reported first-quarter 2024 EPS of $2.13, which topped the Zacks Consensus Estimate by 10.9%. Revenues of $1.20 billion surpassed the Zacks Consensus Estimate by 1.9%.
RMD has an estimated fiscal 2024 earnings growth rate of 17.9% compared with the industry’s 15.7%. The company delivered an average four-quarter earnings surprise of 2.8%.
Encompass Health, carrying a Zacks Rank #2, reported first-quarter 2024 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 20.4%. Net operating revenues of $1.3 billion topped the Zacks Consensus Estimate by 3.6%.
EHC has an estimated long-term earnings growth rate of 15.6% compared with the industry’s 11.7% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.7%.